SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

TG Therapeutics Highlights Data Presentations At ASCO May 29-31, European Hematology Association Congress Jun. 11-14

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually May 29 – June 1, 2020

Benzinga · 05/14/2020 13:30

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually May 29 – June 1, 2020 and the 25th European Hematology Association (EHA) annual congress, to be held virtually June 11 – 14, 2020. Details of the data presentations are included below.

Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are extremely pleased to present data from three combination trials at the upcoming June conferences, which we believe underscores the progress we have made in our combinatorial approach, as well as the potential utility of our lead drug candidates in oncology. We are particularly excited to share the final results from the GENUINE Phase 3 trial, evaluating ublituximab in high-risk CLL patients, which is the first randomized trial to demonstrate a PFS benefit with the addition of an anti-CD20 antibody to ibrutinib, compared to ibrutinib monotherapy. Additionally, it is encouraging to see long-term results from the combination of umbralisib and ibrutinib continue to show the potential versatility of umbralisib in combination regimens.“ Mr. Weiss continued, “Lastly, we look forward to presenting updated results from our proprietary triple combination of ublituximab, umbralisib, and our highly selective, BTK inhibitor, TG-1701, which to date has shown encouraging clinical activity at all dose levels evaluated.”

Data to be presented at the ASCO meeting:

Presentation Title: Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study

  • Abstract Number: 7506
  • Available on Demand: Friday, May 29, 2020 at 8:00 AM ET
  • Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  • Lead Author: Jeff P. Sharman, MD, Willamette Valley Cancer Institute, US Oncology Research, Eugene, OR

The above abstract is now available via the ASCO meeting website at www.asco.org.

Data to be presented at the EHA meeting:

Presentation Title: Long term results of a Phase I/Ib study of ibrutinib in combination with umbralisib in patients with relapsed/refractory CLL or MCL

  • Abstract Number: EP689
  • Available on Demand: Friday, June 12, 2020 at 8:30 CEST
  • Session Title: Chronic lymphocytic leukemia and related disorders - Clinical
  • Lead Author: Matthew Davids, MD, MMSc, Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Presentation Title: Safety and activity of the once daily selective bruton tyrosine kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukemia (CLL) and lymphoma

  • Abstract Number: EP705
  • Available on Demand: Friday, June 12, 2020 at 8:30 CEST
  • Session Title: Chronic lymphocytic leukemia and related disorders - Clinical
  • Lead Author: Chan Cheah, MD, Haematology, Linear Clinical Research, and Sir Charles Gardiner Hospital, Nedlands, Australia

The above abstracts are now available via the EHA meeting website at www.ehaweb.org.

Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.